A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1640-1644

  Sloan, John H ^a   Siegel, Robert W ^a   Ivanova Cox, Yvelina T ^a   Watson, David E ^a   Deeg, Mark A ^a   Konrad, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes; Glucagon; Glucose; Immunoassay; Insulin; Peptide

Indexed keywords

GLUCAGON; INCRETIN; MONOCLONAL ANTIBODY; OXYNTOMODULIN; POLYCLONAL ANTISERUM;

ACCURACY; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; ELECTROCHEMILUMINESCENCE SANDWICH IMMUNOASSAY; ENZYME IMMUNOASSAY; GLUCAGON BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ELECTROCHEMICAL TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON; HUMANS; IMMUNOASSAY; KINETICS; LUMINESCENT MEASUREMENTS; SENSITIVITY AND SPECIFICITY;

EID: 84870662857     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.07.111     Document Type: Article

References (27)

1. Unger R.H., Orci L. Physiology and pathophysiology of glucagon. Physiol Rev 1976, 56:778-826.
2. Drucker D.J., Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 1988, 263:13475-13478.
3. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008, 60:470-512.
4. Dunning B.E., Foley J.E., Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005, 48:1700-1713.
5. Dunning B.E., Gerich J.E. The role of {alpha}-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007, 28:253-283.
6. Muller W.A., Faloona G.R., Aguilar-Parada E., Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970, 283:109-115.
7. Heppner K.M., Habegger K.M., Day J., Pfluger P.T., Perez-Tilve D., Ward B., et al. Glucagon regulation of energy metabolism. Physiol Behav 2010, 100:545-548.
8. Unger R.H., Eisentraut A.M., Mc C.M., Madison L.L. Glucagon antibodies and an immunoassay for glucagon. J Clin Invest 1961, 40:1280-1289.
9. Edgerton D.S., Cherrington A.D. Glucagon as a critical factor in the pathology of diabetes. Diabetes 2011, 60:377-380.
10. Hemminki A., Niemi S., Hautoniemi L., Soderlund H., Takkinen K. Fine tuning of an anti-testosterone antibody binding site by stepwise optimisation of the cdrs. Immunotechnology 1998, 4:59-69.
11. Hermes J.D., Blacklow S.C., Knowles J.R. Searching sequence space by definably random mutagenesis: improving the catalytic potency of an enzyme. Proc Natl Acad Sci U S A 1990, 87:696-700.
12. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997, 15:553-557.
13. Hanes J., Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A 1997, 94:4937-4942.
14. Parmley S.F., Smith G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988, 73:305-318.
15. Soybel D., Jaspan J., Polonsky K., Goldberg I., Rayfield E., Tager H. Differential immunoreactivity of plasma glucagon components in man: studies with different glucagon antibodies. J Clin Endocrinol Metab 1983, 56:612-618.
16. Von Schenck H., Nilsson O.R. Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta 1981, 109:183-191.
17. Sperling M.A., DeLamater P.V., Kazenelson M., Fiser R.H., Fisher D.A. Development and application of a radioimmunoassay for plasma glucagon. Clin Chem 1974, 20:566-570.
18. Hruby V.J. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol Cell Biochem 1982, 44:49-64.
19. Ahn J.M., Medeiros M., Trivedi D., Hruby V.J. Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. J Pept Res 2001, 58:151-158.
20. Ahn J.M., Medeiros M., Trivedi D., Hruby V.J. Development of potent truncated glucagon antagonists. J Med Chem 2001, 44:1372-1379.
21. de Laszlo S.E., Hacker C., Li B., Kim D., MacCoss M., Mantlo N., et al. Potent, orally absorbed glucagon receptor antagonists. Bioorg Med Chem Lett 1999, 9:641-646.
22. Cascieri M.A., Koch G.E., Ber E., Sadowski S.J., Louizides D., de Laszlo S.E., et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem 1999, 274:8694-8697.
23. Madsen P., Ling A., Plewe M., Sams C.K., Knudsen L.B., Sidelmann U.G., et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1h-indol-4-ylmethylene]hydrazide. J Med Chem 2002, 45:5755-5775.
24. Ling A., Plewe M., Gonzalez J., Madsen P., Sams C.K., Lau J., et al. Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 2002, 12:663-666.
25. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., et al. A new glucagon and glp-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009, 5:749-757.
26. Lee Y., Wang M.-Y., Du X.Q., Charron M.J., Unger R.H. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011, 60:391-397.
27. Dinneen S., Alzaid A., Turk D., Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in iddm. Diabetologia 1995, 38:337-343.